Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes-Reference-Cited by-同舟云学术

Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes

Published:2022-12-20 Issue:2 Volume:12 Page:261-273
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Ladumor Mayur K.¹^ORCID,Storelli Flavia¹,Liang Xiaomin²,Lai Yurong²^ORCID,Enogieru Osatohanmwen J.³,Chothe Paresh P.⁴,Evers Raymond⁵,Unadkat Jashvant D.¹

Affiliation:

1. Department of Pharmaceutics University of Washington School of Pharmacy Seattle Washington USA

2. Drug Metabolism Gilead Sciences Inc. Foster City California USA

3. Pharmacokinetics & Drug Metabolism Amgen South San Francisco California USA

4. Global Drug Metabolism and Pharmacokinetics Takeda Development Center USA, Inc. Lexington Massachusetts USA

5. Preclinical Sciences and Translational Safety Janssen Research & Development, LLC Spring House Pennsylvania USA

Funder

Amgen

Gilead Sciences

Janssen Pharmaceuticals

Takeda Pharmaceuticals U.S.A.

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12901

Reference43 articles.

1. Global Epidemiology of Chronic Liver Disease

2. Surgical considerations in hypertension

3. Transection of the oesophagus for bleeding oesophageal varices

4. Liver cirrhosis

5. Utility of quantitative proteomics for enhancing the predictive ability of physiologically based pharmacokinetic models across disease states;Sharma S;J Clin Pharmacol,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disposition of Oral Nalbuphine and Its Metabolites in Healthy Subjects and Subjects with Hepatic Impairment: Preliminary Modeling Results Using a Continuous Intestinal Absorption Model with Enterohepatic Recirculation;Metabolites;2024-08-27

2. Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function;Pharmacology Research & Perspectives;2024-07-11

3. Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects;Pharmaceutics;2024-02-05

4. Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model;CPT: Pharmacometrics & Systems Pharmacology;2023-10-20

5. Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations;Drug Metabolism and Disposition;2023-09-29